title: Expression and prognostic value of EGFR in invasive breast cancer.
abstract: Epidermal growth factor receptor (EGFR) is a membrane receptor expressed in a variety of solid human cancers and directly related with poor prognosis. The objective of this work was to evaluate the EGFR content in breast carcinomas, its possible relationship with different clinical-pathological parameters, and its potential prognostic significance and predictive value. EGFR levels were examined by radioligand binding assays in 846 patients with invasive breast cancer. The median follow-up period was 50 months. There was a wide variability of EGFR levels among the studied tumors (0.01-403 fmol/mg protein). Statistical analysis showed that EGFR levels were significantly higher in younger patients (p=0.0001). EGFR were also notably higher in ER-negative or PgR-negative tumors than in ER-positive (p=0.0001) or PgR-positive tumors (p=0.001). In addition, the presence of high intratumoral EGFR levels (cut-off: 6 fmol/mg protein) was associated with both shorter relapse-free survival (p=0.04) and overall survival (p=0.01) in the group of patients as a whole, as well as with overall survival in the subgroup of patients without any type of systemic adjuvant treatment (p=0.02). However, EGFR levels did not achieve significance as independent prognostic factor in the multivariate analysis. There is a wide variability of intratumoral EGFR levels in breast carcinomas, and these protein levels correlated positively with a poor prognosis in the t univariate analysis. However, further studies are necessary in order to assess the possible clinical value of EGFR in combination with other essential components of the EGFR family network.
authors.affiliation: Servicio de Cirugía General, Hospital de Jove, Avda. Eduardo Castro s/n, Apartado 385, 33290 Gijón, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Quintela
authors.forename: M D
authors.initials: MD
authors.lastname: Corte
authors.forename: M T
authors.initials: MT
authors.lastname: Allende
authors.forename: J
authors.initials: J
authors.lastname: Vazquez
authors.forename: J C
authors.initials: JC
authors.lastname: Rodríguez
authors.forename: M
authors.initials: M
authors.lastname: Bongera
authors.forename: M
authors.initials: M
authors.lastname: Lamelas
authors.forename: L O
authors.initials: LO
authors.lastname: Gonzalez
authors.forename: A
authors.initials: A
authors.lastname: Vega
authors.forename: J L
authors.initials: JL
authors.lastname: García-Muñiz
authors.forename: A
authors.initials: A
authors.lastname: Astudillo
authors.forename: F
authors.initials: F
authors.lastname: Vizoso
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D004273:DNA, Neoplasm / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D011379:Prognosis; D011869:Radioligand Assay; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016019:Survival Analysis
chemical_list: D004273:DNA, Neoplasm; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D066246:ErbB Receptors